1. CD27 is required for protective lytic EBV antigen–specific CD8+ T-cell expansion
- Author
-
Patrick Schuhmachers, Antonino Bongiovanni, Hans J. Stauss, Kyra D. Zens, Angelika Holler, Yun Deng, Hana Zdimerova, Riccarda Capaul, Andrea Zbinden, Laure-Anne Ligeon, Wolfgang Hammerschmidt, Christian Münz, Anne Müller, and Bithi Chatterjee
- Subjects
Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,Immunobiology and Immunotherapy ,Immunology ,Mice, Transgenic ,chemical and pharmacologic phenomena ,CD8-Positive T-Lymphocytes ,medicine.disease_cause ,Biochemistry ,Mice ,Immune system ,Antigen ,Mice, Inbred NOD ,hemic and lymphatic diseases ,medicine ,Animals ,Humans ,Cytotoxic T cell ,CD70 ,B-Lymphocytes ,Immunity, Cellular ,biology ,Chemistry ,Cell Biology ,Hematology ,Cell Transformation, Viral ,Phosphoproteins ,Epstein–Barr virus ,Tumor Necrosis Factor Receptor Superfamily, Member 7 ,Lytic cycle ,Trans-Activators ,biology.protein ,Cancer research ,Antibody ,CD8 - Abstract
Primary immunodeficiencies in the costimulatory molecule CD27 and its ligand, CD70, predispose for pathologies of uncontrolled Epstein-Barr virus (EBV) infection in nearly all affected patients. We demonstrate that both depletion of CD27+ cells and antibody blocking of CD27 interaction with CD70 cause uncontrolled EBV infection in mice with reconstituted human immune system components. While overall CD8+ T-cell expansion and composition are unaltered after antibody blocking of CD27, only some EBV-specific CD8+ T-cell responses, exemplified by early lytic EBV antigen BMLF1-specific CD8+ T cells, are inhibited in their proliferation and killing of EBV-transformed B cells. This suggests that CD27 is not required for all CD8+ T-cell expansions and cytotoxicity but is required for a subset of CD8+ T-cell responses that protect us from EBV pathology.
- Published
- 2021
- Full Text
- View/download PDF